Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04657081 | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | active not recruiting | Phase 1 / Phase 2 | 101 | Taiho Oncology, Inc.INDUSTRY | 3 | Sep 16, 2026 | clinicaltrials |
| NCT05807932 | Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML | recruiting | Phase 1 / Phase 2 | 38 | Heinrich-Heine University, DuesseldorfOTHER | 1 |
| Sep 16, 2026 |
| clinicaltrials |
| NCT06226571 | A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | active not recruiting | Phase 1 | 96 | Syndax PharmaceuticalsINDUSTRY | 6 | Sep 16, 2026 | clinicaltrials |
| NCT06345027 | Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)(CASEY) | recruiting | Phase 1 | 78 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06810583 | A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia | recruiting | Phase 1 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07723703 | Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML(BRAMLIE) | recruiting | Phase 1 | 54 | Amphista Therapeutics LtdINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03471260 | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | recruiting | Phase 1 / Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04547062 | Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)(Tocilam) | completed | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04771130 | A Study of BGB-11417 in Participants With Myeloid Malignancies | recruiting | Phase 1 / Phase 2 | 260 | BeOne MedicinesINDUSTRY | 10 | Sep 14, 2026 | clinicaltrials |
| NCT06846606 | Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | recruiting | Phase 1 | 69 | Auron Therapeutics, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01861314 | Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05520567 | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 70 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05641259 | A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML | recruiting | Phase 1 | 198 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06616636 | A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06969430 | A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 154 | Debiopharm International SAINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05589896 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | active not recruiting | Phase 1 / Phase 2 | 12 | Ossium Health, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | terminated | Phase 1 / Phase 2 | 2 | BlueSphere Bio, IncINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07566585 | Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation | withdrawn | Phase 1 | 0 | BlueSphere Bio, IncINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814339 | Hydrochloroquinine & Decitabine With Venetoclax in AML | not yet recruiting | Phase 1 | 18 | Rutgers, The State University of New JerseyOTHER | 0 | Sep 10, 2026 | clinicaltrials |
| NCT02890329 | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | active not recruiting | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04049539 | Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction | recruiting | Phase 1 / Phase 2 | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04227847 | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | active not recruiting | Phase 1 | 170 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06235801 | A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06888323 | Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment | suspended | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07384715 | First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) | recruiting | Phase 1 | 78 | GenmabINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07796620 | Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI | not yet recruiting | Phase 1 / Phase 2 | 40 | Peking University People's HospitalOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT03386513 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | active not recruiting | Phase 1 / Phase 2 | 179 | AbbVieINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT04655755 | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05010122 | ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05849662 | A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | recruiting | Phase 1 / Phase 2 | 58 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05282459 | Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation | completed | Phase 1 / Phase 2 | 17 | Tian Yi ZhangOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04330820 | Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)(RELAX) | completed | Phase 1 / Phase 2 | 55 | Technische Universität DresdenOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04953780 | Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AML | active not recruiting | Phase 1 | 6 | West Virginia UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07347418 | CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML | recruiting | Phase 1 | 23 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05322850 | Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | recruiting | Phase 1 / Phase 2 | 40 | University of FloridaOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06291987 | Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation(MPN) | recruiting | Phase 1 | 18 | University of ChicagoOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07025564 | MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07177079 | High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 30 | Kittika PoonsombudlertOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07303660 | A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients | recruiting | Phase 1 | 66 | Lomond Therapeutics Holdings, Inc.INDUSTRY | 2 | Aug 31, 2026 | clinicaltrials |
| NCT06152809 | CIML NK Cells With Venetoclax for AML | recruiting | Phase 1 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06690827 | Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05995041 | Universal CAR-T Cells Targeting AML | not yet recruiting | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT02159495 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02494167 | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | completed | Phase 1 | 30 | Baylor College of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03222674 | Multi-CAR T Cell Therapy for Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04033302 | Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials